Notable Labs Debt/Market Cap

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.